Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Long-Term Exercise Maintenance Via Internet Support

Phase 1

Completed

Conditions: Obesity
Inactivity

First Posted Date: 2005-12-01

Last Posted Date: 2010-02-25

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 16000

Registration Number: NCT00260117

Locations: 🇺🇸
Lawrence Berkeley National Laboratory, Berkeley, California, United States

Testosterone and Physical Function in HIV+ Men

Phase 2

Completed

Conditions: HIV Associate Weight Loss

Interventions: Drug: Testosterone enanthate
Drug: Placebo

First Posted Date: 2005-12-01

Last Posted Date: 2018-03-09

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 61

Registration Number: NCT00260143

Locations: 🇺🇸
Charles R. Drew University, Los Angeles, California, United States

Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: vorinostat
Drug: trastuzumab

First Posted Date: 2005-11-24

Last Posted Date: 2014-06-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT00258349

Locations: 🇺🇸
Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States
🇺🇸
Iowa Methodist Medical Center, Des Moines, Iowa, United States
🇺🇸
Woodwinds Health Campus, Woodbury, Minnesota, United States

and more 22 locations

Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: sorafenib tosylate
Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2005-11-21

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00255658

Locations: 🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Stage IV Melanoma
Recurrent Melanoma

Interventions: Drug: carboplatin
Drug: paclitaxel
Biological: bevacizumab
Other: laboratory biomarker analysis

First Posted Date: 2005-11-21

Last Posted Date: 2013-10-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00255762

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Kidney Disease Biomarkers

Completed

Conditions: Kidney Disease
Glomerular Disease
Collapsing Glomerulopathy
Focal Segmental Glomerulosclerosis
Idiopathic Nephrotic Syndrome

First Posted Date: 2005-11-18

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 25

Registration Number: NCT00255398

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Metabolic Analysis in Human Sulfur Amino Acid Deficiency

Not Applicable

Completed

Conditions: Oxidative Stress
Heart Diseases
Diabetes

First Posted Date: 2005-11-15

Last Posted Date: 2010-03-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 15

Registration Number: NCT00253760

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Nodal Marginal Zone Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Vorinostat

First Posted Date: 2005-11-15

Last Posted Date: 2018-03-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00253630

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
City of Hope South Pasadena, South Pasadena, California, United States

and more 2 locations

Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: sorafenib tosylate
Other: laboratory biomarker analysis

First Posted Date: 2005-11-15

Last Posted Date: 2013-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00253578

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Metabolic Effects of Chemical Interactions in Toxicity

Not Applicable

Completed

Conditions: Oxidative Stress

First Posted Date: 2005-11-15

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 15

Registration Number: NCT00253773

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy